To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Summary

Japanese patients with moderate or severe active ulcerative colitis as a subject when ozanimod 0.46 mg or 0.92 mg is orally administered is evaluated about dose response, efficacy and safety with placebo as a control.

Timeline

Start

2019-06-03

Primary completion

2025-09-30

Completion

2025-09-30

Publications

• Hisamatsu T, Fujii T, Nakase H, Matsuoka K, Saruta M, Kobayashi T, Inoue S, Toriyama K, Wang D, Uchikawa Y, Fujimoto G, Hibi T. Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study. Intest Res. 2026 Jul 10. doi: 10.5217/ir.2026.00031. Online ahead of print.

Drugs

Indications